Abstract
Azathioprine is widely used in intestinal bowel disease (IBD) and is an essential element of the therapeutic management. This drug has a recognized potential carcinogenesis and mutagenesis in lymphoproliferative disorders and nonmelanoma skin cancers. Several cohort studies have assessed the risk of myeloid neoplasms (MN), such as acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) in IBD patients exposed to thiopurine before or at the time of inclusion. We describe a case of acute leukemia following azathioprine therapy in a patient with Crohn’s disease; this is a 30-year-old male with an ileocecal Crohn’s disease who developed acute leukemia after 9 years of exposure to azathioprine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
